A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Kura Oncology, Inc.
Eastern Cooperative Oncology Group
Essen Biotech
University of Nebraska
Adela, Inc
Children's Oncology Group
University Medical Center Groningen
Rigshospitalet, Denmark